Anteris six-month 2026: revenue $1.503M (+28% YoY), net loss widens to $52.1M

Anteris Technologies Global Corp.

2026-Q2 EPS reported -$0.58 revenue$1,503,000

Six-month revenue $1.503M vs $1.174M prior year; loss attributable to members $52.118M vs $42.698M (22% worse).
Q2 2026 net operating cash outflows $20.8M; R&D expenses $23.4M driven by PARADIGM trial scaling and manufacturing.
CMS granted Medicare reimbursement for PARADIGM trial procedures under TAVR NCD 20.32; U.S. enrollment began May 2026.
Trial active in U.S., Denmark, Netherlands; regulatory clearance secured in Canada and France; ~1,000-patient randomized study.
No dividend proposed; board appointments of Susan Knight and Stephen Denaro during the quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.